Table 2.
List of Chromosomal Locations of Intergenic Translocations With Potential Fusion Partners
| No. | Year Published in Print/Presented |
Chromosomal Location | Potential Fusion Partner Gene |
Response to ALK TKI at the Time of Publication | Tumor Source | Method of Detection | Variant Frequency in Tumor | FISH/IHC | References |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2019 | 12q23.3 | RIC8B | NR | Tumor | NGS | NR | ND/NR | Zhao, 201944 |
| 2 | 2019 | 2p21 | LOC388942 (LINC01913) | NR | Tumor | NGS | NR | ND/NR | Zhao, 201944 |
| 2020 | 2p21 | LOC388942 (LINC01913) | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 | |
| 3 | 2019 | 2q22.1-q22.2 | LRP1B | NR | Tumor | NGS | NR | ND/NR | Zhao, 201944 |
| 4 | 2019 | 2p16.2 | MIR4431 | NR | Tumor | NGS | NR | ND/NR | Zhao, 201944 |
| 5 | 2019 | 2p23.3 | CENPA/DPYSL5 | PR to crizotinib | Tumor | NGS | NR | +/+ | Fei, 201963 |
| 6 | 2020 | 18q12.1 | CDH2 | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 7 | 2020 | 18q12.2 | CELF4 | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 8 | 2020 | 2p23.3 | CENPA | PR to crizotinib | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 9 | 2020 | 15q13.3 | CHRNA7 | PR to crizotinib | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 10 | 2020 | 2q14.3 | CNTNAP5 | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 11 | 2020 | 2p21 | COX7A2L | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 12 | 2020 | 2p13.2 | DYSF | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 13 | 2020 | 2p16.3 | FSHR | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 14 | 2020 | 13q12.11 | GJB6 | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 15 | 2020 | 3q22.3 | LINC01210 | NR | Tumor | NGs | NR | NR/NR | Tian, 202059 |
| 16 | 2020 | 2p22.3 | MEMO1 | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 17 | 2020 | 2p22.3 | MIR548AD | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 18 | 2020 | 4q31.1 | MGST2 | NR | Tumor | NGs | NR | NR/NR | Tian, 202059 |
| 19 | 2020 | 2q11.2 | PDCL3 | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 20 | 2020 | 2p22.2 | QPCT | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 21 | 2020 | 2p23.3 | RAB10 | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 22 | 2020 | 2p22.1 | SLC8A1 | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 23 | 2020 | 2q32.3 | STK17B | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 24 | 2020 | 6q24.1-q24.2 | VTA1 | NR | Tumor | NGS | NR | NR/NR | Tian, 202059 |
| 25 | 2020 | 2p22.2 | CDC42EP3a | No response to crizotinib and alectinib | Plasma | NGS | 13.0% | ND/+ | Zhang, 202060 |
| 26 | 2020 | 19q13.42 | PR11-433C9.2 (PRPF31) | NR | Tumor | NGS | 18.6% | ND/NR | Zhang, 202060 |
| 27 | 2020 | 3p22.1 | RPSA | NR | Tumor | NGS | 7.9% | ND/+ | Zhang, 202060 |
| 28 | 2020 | 2p23.3 | UBXN2A | NR | Tumor | NGS | 25.4% | ND/NR | Zhang, 202060 |
ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; ND, not done; NGS, next-generation sequencing; NR, not reported; PR, partial response; SD, stable disease; CENPA, centromere protein A; CDC42EP3, CDC42 effector protein 3; CDH2, cadherin 2; CELF4, CUGBP Elav-like family member 4; CNTNAP5, contactin associated protein family member 5; COX7A2L; cytochrome c oxidase subunit 7A2 like; DPYSL5, dihydropyrimidinase like 5; DYSF, dysferlin; FSHR, follicle stimulating hormone receptor; GJB6, gap junction protein beta 6; LINC01210, long intergenic non-protein coding RNA 1210; LINC01913, long intergenic non-protein coding RNA 1913; LRP1B, LDL receptor related protein 1B; MEMO1, mediator of cell motility 1; MIR4431, microRNA 4431; MIR548AD, microRNA 548ad; MGST2, microsomal glutathione S-transferase 2; PDCL3, phosducin like 3; PRPF31, pre-mRNA processing factor 31; QPCT, glutaminyl-peptide cyclotransferase; RAB10, RAB10, member RAS oncogene family; RIC8B, RIC8 guanine nucleotide exchange factor B; RPSA, ribosomal protein SA; SLC8A1, solute carrier family 8 member A1; STK17B, serine/threonine kinase 17b; UBXN2A, UBX domain protein 2A; VTA1, vesicle trafficking 1.
Together with EML4-ALK (E6, A20) and breakpoint is 3’UTR of CDC43EP3 to exon 20 of ALK. +, positive.